Qualigen Therapeutics Inc. (QLGN) is primed for evolution with the beta value of -0.72

Let’s start up with the current stock price of Qualigen Therapeutics Inc. (QLGN), which is $3.91 to be very precise. The Stock rose vividly during the last session to $4.2199 after opening rate of $4.19 while the lowest price it went was recorded $4.0566 before closing at $4.08.

Recently in News on October 28, 2020, Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19. Plans to File IND Application and Initiate Phase 2a Study in First Half of 2021. You can read further details here

My Next COVID-19 Stock Alert Poised For Triple Digit Moves

Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.    

>> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer <<


Qualigen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $21.50 on 03/02/20, with the lowest value was $3.71 for the same time period, recorded on 06/30/20.

Qualigen Therapeutics Inc. (QLGN) full year performance was -37.28%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Qualigen Therapeutics Inc. shares are logging -81.81% during the 52-week period from high price, and 5.39% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $3.71 and $21.50.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 796373 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Qualigen Therapeutics Inc. (QLGN) recorded performance in the market was -3.37%, having the revenues showcasing -36.45% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 111.51M, as it employees total of 5 workers.

The Analysts eye on Qualigen Therapeutics Inc. (QLGN)

During the last month, 0 analysts gave the Qualigen Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 4.85, with a change in the price was noted -1.98. In a similar fashion, Qualigen Therapeutics Inc. posted a movement of -33.62% for the period of last 100 days, recording 1,853,677 in trading volumes.

Technical rundown of Qualigen Therapeutics Inc. (QLGN)

Raw Stochastic average of Qualigen Therapeutics Inc. in the period of last 50 days is set at 7.42%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 2.50%. In the last 20 days, the company’s Stochastic %K was 2.28% and its Stochastic %D was recorded 7.18%.

Considering, the past performance of Qualigen Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -3.37%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -52.90%, alongside a downfall of -37.28% for the period of the last 12 months. The shares increased approximately by -8.31% in the 7-day charts and went up by -14.11% in the period of the last 30 days. Common stock shares were lifted by -36.45% during last recorded quarter.

Get The Best Stocks To Trade Every Day!

Join now to get the Investchronicle.com pre-market morning brief 100% free